Pyrrolo-benzimidazoles, process for their preparation, medicaments containing them and intermediates.
Abstract
New pyrrolo-benzimidazoles of Formula 1in whichR1 represents a hydrogen atom, an alkyl, alkenyl or a cycloalkyl group,R2 represents a hydrogen atom, an alkyl, alkenyl or cyano group, a carbonyl group substituted by a hydroxy, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or with R1 together represents a cycloalkylene group or R1 and R2 together form an alkylidene or cycloalkylidene group,X a valence line, a C1-C4-Alkylene group or the vinylene group,T is oxygen or sulfur,Py represents a 2-, 3- or 4-pyridyl radical which optionally carries an oxygen atom on the ring heteroatom and / or can be substituted by one or more alkyl, alkoxy, hydroxyl, cyano or nitro groups and by halogen, their tautomers and their physiologically tolerable salts, processes for their preparation, medicaments which contain compounds of the formula for the treatment of cardiovascular diseases and compounds of the formula II ain the R1 and R2 have the meanings given in formula I,A and B represent an amino or nitro group or the groupmeanswith the proviso that A and B only NH at the same time2 may mean as intermediates for the preparation of compounds of formula I.

Term
Term ended
Projected expiry passed 9 May 2005, 21.4 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
9 claims: 9 independent, 0 dependent
- 1Compounds of formula I.in whichR1 represents a hydrogen atom, an alkyl, alkenyl or a cycloalkyl group,R2 represents a hydrogen atom, an alkyl, alkenyl or cyano group, a carbonyl group substituted by a hydroxy, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or together with R, represents a cycloalkylene group or R, and R2 together form an alkylidene or cycloalkylidene group,X a valence line, a C1-C4-Alkylene group or the vinylene group,T is oxygen or sulfur,Py represents a 2-, 3- or 4-pyridyl radical which optionally carries an oxygen atom on the ring heteroatom and / or can be substituted by one or more alkyl, alkoxy, hydroxyl, cyano or nitro groups and by halogen, the tautomers of which and their physiologically tolerable salts of inorganic and organic acids. 1. Verbindungen der Formel I in welcher R1 ein Wasserstoffatom, eine Alkyl-, Alkenyl- oder eine Cycloalkylgruppe bedeutet,R2 ein Wasserstoffatom, eine Alkyl-, Alkenyl-, oder Cyangruppe, eine durch eine Hydroxy-, Alkyl-, Alkoxy-, Amino-, Alkylamino-, Dialkylamino- oder Hydrazinogruppe substituierte Carbonylgruppe bedeutet oder mit R, zusammen eine Cycloalkylengruppe darstellt oder R, und R2 zusammen eine Alkyliden- oder Cycloalkylidengruppe bilden,X einen Valenzstrich, eine C1-C4-Alkylengruppe oder die Vinylengruppe bedeutet,T gleich Sauerstoff oder Schwefel bedeutet,Py einen 2-, 3- oder 4-Pyridylrest darstellt, der gegebenenfalls am Ringheteroatom ein Sauerstoffatom traegt und/ oder durch eine oder mehrere Alkyl-, Alkoxy-, Hydroxy-, Cyano- oder Nitrogruppen, sowie durch Halogen substituiert sein kann, deren Tautomere und deren physiologisch vertraegliche Salze anorganischer und organischer Saeuren.
- 2Verbindungen gemäß Anspruch 1, in denen R1 Wasserstoff, Methyl, Ethyl, 2-Propyl, 2-Methyl-propyl oder Cyclopentyl, R2 Wasserstoff, Methyl, Ethyl, Ethoxycarbonyl oder Hydrazinocarbonyl, R1 und R2 zusammen mit dem C-Atom, an das sie gebunden sind, einen Cyclopentan-Ring oder zusammen einen Isopropyliden-Rest bilden, X eine Valenzbindung, eine Methylen-, Ethylen- oder Vinylgruppe, T Sauerstoff oder Schwefel und Py einen Pyridylen-N-oxid-Rest oder einen Pyridyl-Rest bedeuten, der ein- oder mehrfach durch Hydroxyl, Methoxy, Methyl oder Halogen substituiert sein kann, deren Tautomere und deren physiologisch verträgliche Salze. 2nd Compounds according to claim 1, in which R1 Hydrogen, methyl, ethyl, 2-propyl, 2-methyl-propyl or cyclopentyl, R2 Hydrogen, methyl, ethyl, ethoxycarbonyl or hydrazinocarbonyl, R1 and R2 together with the carbon atom to which they are attached form a cyclopentane ring or together form an isopropylidene radical, X is a valence bond, a methylene, ethylene or vinyl group, T is oxygen or sulfur and Py is a pyridylene N-oxide -Rest or a pyridyl radical, which can be substituted one or more times by hydroxyl, methoxy, methyl or halogen, their tautomers and their physiologically tolerable salts.
- 3Verbindungen gemäß Anspruch 1 oder 2, in denen T Sauerstoff, X eine Valenzbindung, R1 Wasserstoff oder Methyl, R2 Methyl, Ethyl oder Ethoxycarbonyl und Py einen Pyridin-N-oxid-Rest oder einen Pyridyl-Rest darstellen, der durch Hydroxy oder Methyl substituiert sein kann, deren Tautomere und deren physiologisch verträgliche Salze. 3rd Compounds according to claim 1 or 2, in which T is oxygen, X is a valence bond, R1 Hydrogen or methyl, R2 Methyl, ethyl or ethoxycarbonyl and Py represent a pyridine-N-oxide residue or a pyridyl residue which can be substituted by hydroxy or methyl, their tautomers and their physiologically tolerable salts.
- 4Verbindungen gemäß Anspruch 1, ausgewählt hiervon:7,7 Dimethyl-2-(4-pyridyl)-6,7-dihydro-3H,5H-pyrrolo[2,3-f] - benzimidazol-6-on7,7-Dimethyl-2-(4-N-oxy-pyridyl)-6,7-dihydro-3H,5H-pyrrolo-[2,3-f]benzimidazol-6-on7-Ethoxycarbonyl-7-methyl-2-(4-pyridyl)-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-on7,7-Dimethyl-2-(4-(2-methyl-pyridyl))-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-on 4th Compounds according to claim 1 selected from:7.7 dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one7,7-dimethyl-2- (4-N-oxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one7-ethoxycarbonyl-7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one7,7-dimethyl-2- (4- (2-methyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one
- 5Process for the preparation of compounds of formula I.in whichR represents a hydrogen atom, an alkyl, alkenyl or a cycloalkyl group,R2 represents a hydrogen atom, an alkyl, alkenyl or cyano group, a carbonyl group substituted by a hydroxyl, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or with R1 together represents a cycloalkylene group or R1 and R2 together form an alkylidene or cycloalkylidene group,X a valence line, a C1-C4-Alkylene group or the vinylene group,T is oxygen or sulfur,Py represents a 2-, 3- or 4-pyridyl radical which optionally carries an oxygen atom on the ring heteroatom and / or by one or more alkyl, Alkoxy, hydroxyl, cyano or nitro groups, and may be substituted by halogen, their tautomers and their physiologically tolerable salts of inorganic and organic acids, characterized in that in a manner known per sea) a compound of formula XIIin the R1 and R2 have the meaning given above, with a compound of the formula XIVin which Py and X have the meaning given and Y is either hydrogen or an easily removable radical, is reacted and the compound obtained is cyclized in an acidic medium, orb) a compound of the formula XIXor Formula XXin which R1, R2, T, Py and X have the meanings given above, reduced and then cyclized orc) a compound of formula XXVI.with a reactive carboxylic acid derivative of the formula XXVIIacylated and cyclized, where R1, R2, Py, X and Hal have the meanings given, ord) a compound of formula XXVIIIwith a reactive carboxylic acid derivative of the formula XXIXconverted to corresponding hydrazides and then cyclized under alkaline conditions, where R1, R2' Py and X have the meanings indicated and then, if desired, compounds of the formula I obtained are converted into other compounds of the formula I and, if desired, the compounds with inorganic or organic acids are converted into physiologically tolerable salts. 5. Verfahren zur Herstellung von Verbindungen der Formel I in welcher R ein Wasserstoffatom, eine Alkyl-, Alkenyl- oder eine Cycloalkylgruppe bedeutet,R2 ein Wasserstoffatom, eine Alkyl-, Alkenyl-, oder Cyangruppe, eine durch eine Hydroxy-, Alkyl-, Alkoxy-, Amino-, Alkylamino-, Dialkylamino- oder Hydrazinogruppe substituierte Carbonylgruppe bedeutet oder mit R1 zusammen eine Cycloalkylengruppe darstellt oder R1 und R2 zusammen eine Alkyliden- oder Cycloalkylidengruppe bilden,X einen Valenzstrich, eine C1-C4-Alkylengruppe oder die Vinylengruppe bedeutet,T gleich Sauerstoff oder Schwefel bedeutet,Py einen 2-, 3- oder 4-Pyridylrest darstellt, der gegebenenfalls am Ringheteroatom ein Sauerstoffatom traegt und/ oder durch eine oder mehrere Alkyl-, Alkoxy-, Hydroxy-, Cyano- oder Nitrogruppen, sowie durch Halogen substituiert sein kann, deren Tautomere und deren physiologisch vertraegliche Salze anorganischer und organischer Saeuren, dadurch gekennzeichnet, daß man in an sich bekannter Weisea) eine Verbindung der Formel XII in der R1 und R2 die oben angegebene Bedeutung besitzen, mit einer Verbindung der Formel XIV in der Py und X die angegebene Bedeutung besitzen und Y entweder Wasserstoff oder einen leicht abspaltbaren Rest darstellt, umsetzt und die erhaltene Verbindung in saurem Medium cyclisiert, oderb) eine Verbindung der Formel XIX oder der Formel XX in denen R1, R2, T, Py und X die oben angegebenen Bedeutungen besitzen, reduziert und anschließend cyclisiert oderc) eine Verbindung der Formel XXVI mit einem reaktiven Carbonsäure-Derivat der Formel XXVII acyliert und cyclisiert, wobei R1, R2, Py, X und Hal die angegebenen Bedeutungen haben, oderd) eine Verbindung der Formel XXVIII mit einem reaktiven Carbonsäure-Derivat der Formel XXIX zu entsprechenden Hydraziden umgesetzt und diese dann unter alkalischen Bedingungen cyclisiert, wobei R1, R2' Py und X die angegebenen Bedeutungen haben und anschließend gewünschtenfallls erhaltene Verbindungen der Formel I in andere Verbindungen der Formel I überführt sowie gewünschtenfalls die Verbindungen mit anorganischen oder organischen Säuren in physiologisch verträgliche Salze überführt.
- 8Verbindungen der Formel XXXin der R1 ein Wasserstoffatom, eine Alkyl-, Alkenyl- oder eine Cycloalkylgruppe bedeutet,R2 ein Wasserstoffatom, eine Alkyl-, Alkenyl-, oder Cyangruppe, eine durch eine Hydroxy-, Alkyl-, Alkoxy,-Amino-, Alkylamino-, Dialkylamino- oder Hydrazinogruppe substituierte Carbonylgruppe bedeutet oder mit R1 zusammen eine Cycloalkylengruppe darstellt oder R1 und R2 zusammen eine Alkyliden- oder Cycloalkylidengruppe bilden,A NH2, N02 oder Py-X-NH undB NH2, N02 oder Py-X-NH bedeuten, wobeiX einen Valzenzstrich, eine C1-C4-Alkylengruppe oder die Vinylengruppe bedeutet undPy einen 2-, 3- oder 4-Pyridylrest darstellt, der gegebenenfalls am Ringheteroatom ein Sauerstoffatom trägt und/oder durch eine oder mehrere Alkyl-, Alkoxy-, Hydroxy-, Cyano-oder Nitrogruppen sowie durch Halogen substituiert sein kann,mit der Maßgabe, daß A und B nur gleichzeitig NH2 bedeuten dürfen. 8th. Compounds of formula XXXin theR1 represents a hydrogen atom, an alkyl, alkenyl or a cycloalkyl group,R2 represents a hydrogen atom, an alkyl, alkenyl or cyano group, a carbonyl group substituted by a hydroxy, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or with R1 together represents a cycloalkylene group or R1 and R2 together form an alkylidene or cycloalkylidene group,A NH2, N02 or Py-X-NH andB NH2, N02 or Py-X-NH, whereX a valence line, a C1-C4-Alkylene group or the vinylene group means andPy represents a 2-, 3- or 4-pyridyl radical which optionally carries an oxygen atom on the ring hetero atom and / or can be substituted by one or more alkyl, alkoxy, hydroxyl, cyano or nitro groups and by halogen,with the proviso that A and B only NH at the same time2 may mean.
- 9Use of compounds according to claim 8 for the preparation of compounds of formula I. 9. Verwendung von Verbindungen gemäß Anspruch 8 zur Herstellung von Verbindungen der Formel I.
Independent claims9
231 paragraphs in 4 sections, as filed
The present invention relates to new pyrrolo-benzimidazoles of the general formula I.<chemistry id="chem0001" num="0001"><img file="EP0161632A2_D0001.tif" /></chemistry>in which<ul id="ul0001" list-style="none"><li>R represents a hydrogen atom, an alkyl, alkenyl or a cycloalkyl group,</li><li>R<sub>2</sub> represents a hydrogen atom, an alkyl, alkenyl or cyano group, a carbonyl group substituted by a hydroxyl, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or with R<sub>1</sub> together represents a cycloalkylene group or R<sub>1</sub> and R<sub>2</sub> together form an alkylidene or cycloalkylidene group,</li><li>X a valence line, a C<sub>1</sub>-C<sub>4</sub>-Alkylene group or the vinylene group,</li><li>T is oxygen or sulfur,</li><li>Py represents a 2-, 3- or 4-pyridyl radical which optionally carries an oxygen atom on the ring heteroatom and / or can be substituted by one or more alkyl, alkoxy, hydroxyl, cyano or nitro groups and by halogen, the tautomers of which and their physiologically tolerable salts of inorganic and organic acids and processes for their preparation, and medicaments containing these compounds.</li></ul>
Since the compounds of general formula I in the event that R<sub>7</sub> not equal to R<sub>2</sub> has an asymmetric carbon atom, the invention also relates to the optically active forms and racemic mixtures of these compounds. These new compounds of the present invention have valuable pharmacological properties, in particular they increase heart strength and / or lower blood pressure and / or influence platelet aggregation and improve microcirculation.
In the formulas listed below, in particular formula I, the substituents R<sub>1</sub> and R<sub>2</sub> be the same or different and are hydrogen, a straight-chain or branched alkyl or alkenyl group with 1-6 or 2-6 carbon atoms, a cyano group or one with a hydroxyl, alkyl, alkoxy, amino, alkylamino, dialkylamino, or hydrazino group substituted carbonyl group, where each of the aforementioned alkyl parts can be straight-chain or branched from 1-6 or 2-6 carbon atoms. In particular, however, come hydrogen, the methyl, ethyl, allyl, cyano, carboxy, acetyl, propionyl, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl and hydrazinocarbonyl group for R, and R<sub>2</sub> in question.
Provides only R<sub>2</sub> represents a hydrogen atom, then R is a straight-chain alkyl group with 1-6 carbon atoms or a branched alkyl group, a cycloalkyl or alkenyl group with 3-7 carbon atoms, a cyano group or one with an alkyl, alkoxy, amino, alkylamino, Dialkylamino or hydrazino group substituted carbonyl group. In this sense, preference is given to methyl, ethyl, isopropyl, isobutyl, pentyl, cyclopentyl, cyclohexyl, allyl, cyano, acetyl, propionyl, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl , Dimethylaminocarbonyl and hydrazinocarbonyl group.
R, and R<sub>2</sub> can together with the carbon atom to which they are attached also form a cycloalkyl ring with 3-8 carbon atoms, preferably it is the spirocyclopropyl, spirocyclobutyl, spirocyclopentyl and spirocyclohexyl group.
R<sub>1</sub> and R<sub>2</sub> together can also be a C<sub>2</sub>-C<sub>6</sub>-Alkyliden- or C<sub>3</sub>-C<sub>8</sub>-Cycloalkylidene form, preferably it is the isopropylidene group.
Alkyl or alkoxy substituents of the pyridine ring can contain 1-6, preferably 1-4 C atoms. Methyl and ethyl or methoxy and ethoxy is preferred. Halogen is to be understood as fluorine, chlorine and bromine, preferably chlorine.
Py represents a 2-, 3- or 4-pyridyl radical which optionally carries an oxygen atom on the ring heteroatom and / or can be substituted by one or more alkyl, alkoxy, hydroxyl, cyano or nitro groups and by halogen and X is a valence line, in this sense 2-pyridyl-, 2- (N-oxypyridyl) -, 2- (5-n-butyl-pyridyl) -, 3-pyridyl-, 3- (N- Oxy-pyridyl) -, 3- (6-methyl-pyridyl) -, 3- (6-cyano-pyridyl) -, 3- (6-nitro-pyridyl) -, 3- (6-hydroxy-pyridyl) -, 3- (2-methoxy-6-methyl-pyridyl) -, 4-pyridyl, 4- (N-oxy-pyridyl) -, 4- (2-methyl-pyridyl) -, 4- (2-ethyl-pyridyl) ) -, 4- (2-hydroxypyridyl) -, 4- (2-methoxypyridyl) -, 4- (2-nitro-pyridyl) -, 4- (2-chloropyridyl) - and the 4- (3-hydroxy-pyridyl) residue.
X means a C<sub>1</sub>-C<sub>4</sub> Alkylene group or the vinylene group and Py a 2-, 3- or 4-pyridyl radical, so in this sense the 3-pyridyl-methyl-, 3-pyridyl-ethyl-, 3-pyridyl-vinyl-, 4-pyridyl- methyl, 4-pyridyl-ethyl and 4-pyridyl-vinyl radical.
Preferred pyrrolo-benzimidazoles of the general formula I are compounds in which R<sub>1</sub> Hydrogen, methyl, ethyl, 2-prcpyl, 2-methyl-propyl or cyclopentyl, R<sub>2 </sub>Hydrogen, methyl, ethyl, ethoxycarbonyl or hydrazinocarbonyl, R<sub>1</sub> and R<sub>2</sub> together with the carbon atom to which they are attached form a cyclopentane ring or together an isopropylidene radical, X is a valence bond, a methylene, ethylene or vinylene group, T is oxygen or sulfur and Py is a pyridyl-N-oxide Radical or a pyridyl radical, which can be substituted one or more times by hydroxyl, methoxy, methyl or halogen.
Compounds of the formula I are particularly preferred in which T is oxygen, X is a valence bond, R<sub>1</sub> Hydrogen or methyl, R<sub>2</sub> Methyl, ethyl or ethoxycarbonyl and Py represent a pyridine-N-oxide residue or a pyridyl residue, which may be substituted by hydroxy or methyl.
The compounds of the general formula I are first prepared in such a way that either<ul id="ul0002" list-style="none"><li>a) o-Cyanbenzylnitrile II<chemistry id="chem0002" num="0002"><img file="EP0161632A2_D0002.tif" /></chemistry>with a compound of general formula III<chemistry id="chem0003" num="0003"><img file="EP0161632A2_D0003.tif" /></chemistry>or IV<chemistry id="chem0004" num="0004"><img file="EP0161632A2_D0004.tif" /></chemistry>in which R<sub>1</sub> has the meaning given, R<sub>3</sub> a C<sub>2</sub>-C<sub>6</sub>Alkylene group and Z represents a cleavable group, alkylated to compounds of general formula V,<chemistry id="chem0005" num="0005"><img file="EP0161632A2_D0005.tif" /></chemistry>in which R<sub>1</sub> and R<sub>2</sub> have the meaning given and then cyclize in an acid medium to give compounds of the general formula VI,<chemistry id="chem0006" num="0006"><img file="EP0161632A2_D0006.tif" /></chemistry>in which R<sub>1</sub> and R<sub>2</sub> have the meaning given above, or</li><li>b) alkylated isoquinoline-1,3-dione with a compound of general formula III or IV to a compound of general formula VI or</li><li>c) isoquinoline-1,3-dione with a compound of the general formula VII<chemistry id="chem0007" num="0007"><img file="EP0161632A2_D0007.tif" /></chemistry>in which R<sub>4</sub> and R<sub>s</sub> Are hydrogen and / or alkyl groups or R<sub>4</sub> together with R<sub>s</sub> a C<sub>3</sub>-C<sub>7</sub>-Cycloalkylene group forms, condensed in the presence of a base to compounds of general formula VIII<chemistry id="chem0008" num="0008"><img file="EP0161632A2_D0008.tif" /></chemistry>in which R<sub>4</sub> and R<sub>5</sub> has the meaning given above and, if appropriate, subsequently compounds of the general formula VIII are converted by catalytic hydrogenation into compounds of the general formula VI in which R<sub>1</sub> or R<sub>2</sub> is equal to hydrogen.</li></ul>
A cleavable group Z of the compounds of the formula III or IV is generally a halogen atom, chlorine, bromine and iodine being preferred.
The cyclization of a compound of formula V takes place in an acidic medium, preferably in the presence of mineral acids such as hydrochloric acid or sulfuric acid.
The condensation of isoquinoline-1,3-dione with a compound of the formula VII takes place in the presence of a base, preferably KOH or NaOH.
The catalytic hydrogenation of compounds of the formula VIII is preferably carried out with Pd / C in alcoholic media.
Compounds of the formula VI and the process steps listed above are described in German patent application P 34 10 168.3.
The compounds of the general formula VI thus obtained are converted in a known manner into compounds of the general formula IX by nitration in the 7-position<chemistry id="chem0009" num="0009"><img file="EP0161632A2_D0009.tif" /></chemistry>from which by Hoffmann degradation with hypohalide according to NA Joensson and P. Moses, Acta Chem. Scand. B 28, 225-232 (1974) compounds of the general formula X can be obtained,<chemistry id="chem0010" num="0010"><img file="EP0161632A2_D0010.tif" /></chemistry>in which R, and R<sub>2</sub> have the meaning given above.
By reducing the nitro group into an amino group, compounds of the general formula XI are obtained<chemistry id="chem0011" num="0011"><img file="EP0161632A2_D0011.tif" /></chemistry>in which R and Rz have the meaning given above, which can also be obtained in a known manner from correspondingly substituted derivatives of 2,4-diaminophenylacetic acid by ring closure (see: RC Elderfield (Ed.), PL Julian, EW Meyer, HC Printy, Heterocycl. Comp. Vo. 3, 126-186, John Wiley & Sons 1952, New York).
The compounds of the general formula XI thus obtained are known in a known manner by acetylation of the amino group in the 6-position, nitration in the 5-position, removal of the protective group and reduction of the nitro group in the 5-position in a 5,6-diamino-indoline-2- on the general formula XII<chemistry id="chem0012" num="0012"><img file="EP0161632A2_D0012.tif" /></chemistry>in the R, and R<sub>2</sub> have the meaning given above.
The compounds of general formula I can also be prepared in such a way that<ul id="ul0003" list-style="none"><li>d) compounds of the general formula XII are obtained by using an oxindole derivative of the general formula XIII protected against nitrogen<chemistry id="chem0013" num="0013"><img file="EP0161632A2_D0013.tif" /></chemistry>in the R<sub>1</sub> and R<sub>2</sub> is hydrogen and A is a protective group, for example an acetyl or benzyl protective group, alkylated with compounds of the general formula III or IV with the meaning given above to other compounds of the general formula XIII, in which R<sub>1</sub> and R<sub>2</sub> have the meaning given above, but not R<sub>1</sub> = R<sub>2</sub> = H is. After splitting off a benzyl protective group, for example by sodium in liquid ammonia or an acetyl protective group in an acidic or basic medium, an indolin-2-one derivative of the general formula XIII is obtained in which A is hydrogen and R<sub>1</sub> and R<sub>2</sub> have the meaning given above, but not R, = R<sub>2</sub> = Mean hydrogen.</li></ul>
The compounds of general formula XIII obtained in this way are known in a known manner by nitration in the 5-position, subsequent reduction of the nitro group to the amino function, acetylation of the amino group in the 5-position, nitration in the 6-position, elimination of the protective group and reduction of the nitro group in the 5- Position in a corresponding 5,6-diamino-indolin-2-one derivative of the general formula XII with the meaning given above.
The inventive process for the preparation of compounds of formula I is carried out by reacting a compound of formula XII with a compound of formula XIV<chemistry id="chem0014" num="0014"><img file="EP0161632A2_D0014.tif" /></chemistry>in which Py and X have the meaning given and Y is either hydrogen or an easily removable radical, is reacted and the compounds obtained are cyclized to a compound of the formula I or its tautomeric form, and if desired converting a compound of the formula I obtained according to the invention into another compound of the formula I or its tautomer and / or converting a obtained compound of the general formula I and its tautomer into a physiologically tolerable acid addition salt with an inorganic or organic acid.
Compounds of the formula XIV are understood to mean, in particular, aldehydes, and also acid halides such as acid chlorides, carboxylic acid esters such as methyl and ethyl esters and other activated carboxylic acid derivatives, such as, for example, anhydrides.
If the compound of the formula XIV is an aldehyde, the reaction to the Schiff base with compounds of the general formula XII preferably takes place in an alcoholic medium, the subsequent cyclization and oxidation to the compounds of the general formula I is carried out by heating the reaction mixture to reflux in the presence of Atmospheric oxygen and catalytic amounts of acid such as toluenesulfonic acid.
If the compound of general formula XIV is a carboxylic acid derivative, the reaction with compound of general formula XII to the amide takes place in inert solvents, preferably methylene chloride, and the subsequent cyclization to compounds of general formula I is carried out in an acidic medium, preferably in the presence of mineral acids such as H.<sub>2</sub>S0<sub>4</sub> or HCl in alcoholic solution.
Compounds of the general formula I are also obtained by<ul id="ul0004" list-style="none"><li>e) starting from compounds of the formula XV<chemistry id="chem0015" num="0015"><img file="EP0161632A2_D0015.tif" /></chemistry></li></ul>in which R<sub>1</sub>, R<sub>2</sub> and T have the meaning given above, by reaction with compounds of the general formula XIV, in which Y represents an easily removable radical, in a generally known manner compounds of the formula XVII<chemistry id="chem0016" num="0016"><img file="EP0161632A2_D0016.tif" /></chemistry>or XVIII<chemistry id="chem0017" num="0017"><img file="EP0161632A2_D0017.tif" /></chemistry>in which R<sub>:</sub>, R<sub>2</sub>, T, Py and X have the meanings given above, obtained and in a known manner by nitration in compounds of the general formula XIX<chemistry id="chem0018" num="0018"><img file="EP0161632A2_D0018.tif" /></chemistry>or XX<chemistry id="chem0019" num="0019"><img file="EP0161632A2_D0019.tif" /></chemistry>in which R<sub>1</sub>, R<sub>2</sub>, T, Py and X have the meanings given above.
After hydrogenation of the nitro group in the compounds of general formula XIX or XX to the corresponding amine compounds XXI<chemistry id="chem0020" num="0020"><img file="EP0161632A2_D0020.tif" /></chemistry>or XXII<chemistry id="chem0021" num="0021"><img file="EP0161632A2_D0021.tif" /></chemistry>in which R<sub>1</sub>, R<sub>2</sub>, T, Py and X have the meaning given above, the desired compounds of the general formula I are obtained by cyclization.
Compounds of formula XVI are obtained, for example, by nitration of compounds of general formula XXIII<chemistry id="chem0022" num="0022"><img file="EP0161632A2_D0022.tif" /></chemistry>in the 5-position and subsequent reduction of the nitro to the amino group.
The compounds of general formula I can also be prepared in such a way that<ul id="ul0005" list-style="none"><li>f) acetylated compounds of the general formula XV or XVI on the 6- or 5-amino function in a generally known manner and compounds of the general formula XXIV by subsequent nitration and cleavage of the acetyl protective groups<chemistry id="chem0023" num="0023"><img file="EP0161632A2_D0023.tif" /></chemistry>in which R<sub>:</sub>, R<sub>2</sub> and T have the meaning given above. Reactions with compounds of the general formula XIV can also be used to obtain compounds of the general formula XIX or XX in the manner described above.</li><li>g) Compounds of the general formula I or their tautomeric forms and the various intermediates leading to them can, in addition to the processes described above, also by various processes known from the literature, for example from compounds of the general formula XXVI<chemistry id="chem0024" num="0024"><img file="EP0161632A2_D0024.tif" /></chemistry>with Py and X in the meaning given above (see RC Elderfield (Ed.), PL Julian, EW Meyer, BC Printy, Heterocycl. Comp. Vol. 3, 126-186, John Wiley Sons 1952, New York) .</li></ul>
For example, compounds of the formula XXVI with a reactive carboxylic acid derivative of the formula XXVII, preferably acid chloride,<chemistry id="chem0025" num="0025"><img file="EP0161632A2_D0025.tif" /></chemistry>acylated and cyclized with Lewis acids (AlCl3) (Stolle synthesis), where Hal can be chlorine, bromine or iodine and R<sub>1</sub> and R<sub>2</sub> have the meaning given above. The 7-monosubstituted compounds of the formula 1 can preferably be prepared by this method.
According to another variant, compounds of the formula XXVIII<chemistry id="chem0026" num="0026"><img file="EP0161632A2_D0026.tif" /></chemistry>with a reactive carboxylic acid derivative of the formula XXIX, preferably acid chloride,<chemistry id="chem0027" num="0027"><img file="EP0161632A2_D0027.tif" /></chemistry>in the round <sub>R2</sub> have the meaning given above, converted to corresponding hydrazides and then cyclized under alkaline conditions. (Brunner synthesis)
Reactive carboxylic acid derivatives of the formulas XXVII and XXIX are in particular acid chlorides, anhydrides or mesyl and tosyl esters.
Corresponding compounds of the general formula I or the intermediates leading to them are also obtained by reacting <sub>P</sub>henyl hydrazine or correspondingly substituted phenyl hydrazines according to the method described by K. Brunner, Mo'natsh. f. Chemistry 18, 95 (1897) described manner or, for example, by alkylation of 2,4-dinitrochlorobenzene with suitably substituted malonic acid derivatives, for example the sodium salt of methylmalonate diethyl ester, by methods known from the literature, subsequent reduction of the nitro groups and ring closure to give compounds of the general formula XV.
The above-mentioned hydrogenation of a nitro group in the processes mentioned under a) - g) to give compounds of the general formula I is preferably carried out in a solvent or solvent mixture such as water, methanol, ethanol, glacial acetic acid, ethyl acetate or dimethylformamide with hydrogen in the presence of a catalyst such as Raney Nickel, platinum or palladium / coal, with metals such as iron, tin or zinc in the presence of an acid, with salts such as iron (II) sulfate, tin (II) chloride, Sodium sulfide, sodium hydrogen sulfite or sodium dithionite or with hydrazine in the presence of Raney nickel at temperatures between 0 and 100 ° C, but preferably at room temperature.
The cyclizations to the desired compounds of the general formula I mentioned in processes a) - g) above are preferably carried out in a solvent or solvent mixture such as ethanol, isopropanol, glacial acetic acid, benzene, toluene, chlorobenzene, glycol, ethylene glycol dimethyl ether, sulfolane or dimethylformamide Temperatures between 0 ° C and 220 ° C, but preferably at the boiling point of the reaction mixture, optionally in the presence of a condensing agent such as phosphorus oxychloride, thionyl chloride, p-toluenesulfonic acid, hydrochloric acid, sulfuric acid, phosphoric acid, <sub>P</sub>olyphosphoric acid or optionally also in the presence of a base such as sodium hydroxide, sodium methylate or potassium tert-butoxide. However, the cyclization can also be carried out without a solvent and / or condensing agent.
The subsequent conversion of a compound of the formula I into another compound of the formula I relates, for example, to the oxidation of the pyridyl radical into the corresponding N-oxide, which is mainly caused by H<sub>2</sub>O<sub>2</sub> in acetic acid, and the hydrogenation of an unsaturated substituent. This is particularly true for the hydrogenation of a vinyl compound (X = -CH =<sub>CH</sub>-) in the corresponding ethyl compound.
The subsequent conversion of a compound of formula I in which R and R<sub>2</sub> mean hydrogen, in another compound of the formula I also relates, for example, to the reaction with compounds of the general formula VII with the meaning given above in the presence of a base such as ammonia or triethylamine in an alcoholic solution. This applies in particular to the conversion of compounds of the general formula I in which R, = R<sub>2</sub> = Mean hydrogen to compounds of general formula I in which R, together with R<sub>2</sub> the isopropylidene group, the cyclopentylidene or cyclohexylidene group, and, if appropriate, their hydrogenation to give the corresponding compounds of the general formula I, i n those R, or R<sub>2</sub> is equal to hydrogen.
In addition, the subsequent conversion relates to compounds of the general formula I in which R, or R<sub>2</sub> represents a carboxyl group or a reactive derivative such as carboxylic acid ester or acid chloride, which with hydrazine, ammonia, a primary or secondary amine or a reactive derivative thereof to give new compounds of general formula I, in which R<sub>1</sub> or R<sub>2</sub> is a carbonyl group substituted by an amino, alkylamino, dialkylamino or hydrazino group. The subsequent conversion also relates to compounds of the general formula I in which R<sub>1</sub> or R<sub>2</sub> represents an aminocarbonyl group to those in which R<sub>1</sub> or R<sub>2</sub> is a cyano group, and the subsequent conversion of a cyano group into a carboxyl, aminocarbonyl or alkoxycarbonyl group. These conversions are all carried out according to generally accepted methods known from the literature.
The subsequent conversion to compounds of the general formula I and the intermediates leading to the compounds of the general formula I in which T represents a sulfur atom, from those in which T represents an oxygen atom, is carried out according to methods known from the literature with a reagent which transfers the sulfur atom, such as, for example, phosphorus pentasulfide or 2,4-bis (4-methoxyphenyl) -2,4-dithioxo-1,3,2,4-dithiadiphosphane in a suitable solvent such as Tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, benzene, toluene or pyridine at temperatures between 0 ° C and the boiling point of the reaction mixture.
The compounds of the general formula XII, XIX, XX, XXIV and XXV, in which<ul id="ul0006" list-style="none"><li>R represents a hydrogen atom, an alkyl, alkenyl or a cycloalkyl group,</li><li>R<sub>2</sub> represents a hydrogen atom, an alkyl, alkenyl or cyano group, a carbonyl group substituted by a hydroxy, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or with R<sub>1</sub> form a cycloalkylene group, and where applicable</li><li>X a valence line, a C<sub>1</sub>-C<sub>4</sub>-Alkylene group or the vinyl group means</li><li>T is oxygen or sulfur and</li><li>Py represents a 2-, 3- or 4-pyridyl radical which may optionally be substituted by one or more alkyl, alkoxy, hydroxyl, cyano or nitro groups and by halogen,</li><li>are new and also the subject of the invention.</li></ul>
In addition to the compounds mentioned in the examples, compounds of the formula XII according to the invention are the following:<ul id="ul0007" list-style="none"><li>5,6-diamino-3-acetyl-indolin-2-one 5,6-diamino-3-acetyl-3-methyl-indolin-2-one 5,6-diamino-3-allyl-indolin-2-one 5 , 6-diamino-3-cyano-3-methyl-indolin-2-one 5,6-diamino-3-cyclohexyl-indolin-2-one 5,6-diamino-3-cyclopentyl-indolin-2-one 5, 6-diamino-3,3-diallyl-indolin-2-one 5,6-diamino-3-ethoxycarbonyl-indolin-2-one 5,6-diamino-3-ethoxycarbonyl-3-ethyl-indolin-2-one 5 , 6-diamino-3-ethoxycarbonyl-3-methyl-indolin-2-one 5,6-diamino-3-ethyl-indolin-2-one 5,6-diamino-3-methoxycarbonyl-indolin-2-one 5,6-diamino-3-methoxycarbonyl-3-methyl-indolin-2-one 5,6-diamino-3-methyl-indolin-2-one 5,6-diamino-3- (3-pentyl) indoline 2-one 5,6-diamino-3- (2-propyl) indolin-2-one 5 ', 6'-diamino-spiro [cyclohexan-1,3'-indoline] -2'-one</li></ul>
In addition to the compounds mentioned in the examples, compounds of the formula XXV according to the invention are the following:<ul id="ul0008" list-style="none"><li>5-amino-6-nitro-3-acetyl-indolin-2-one 5-amino-6-nitro-3-acetyl-3-methyl-indolin-2-one 5-amino-6-nitro-3-allyl- indolin-2-one 5-amino-6-nitro-3-cyano-3-methyl-indolin-2-one 5-amino-6-nitro-3-cyclohexyl-indolin-2-one 5-amino-6-nitro -3-cyclopentyl-indolin-2-one 5-amino-6-nitro-3,3-diallyl-indolin-2-one 5-amino-6-nitro-3-ethoxycarbonyl-indolin-2-one 5-amino- 6-nitro-3-ethoxycarbonyl-3-ethyl-indolin-2-one 5-amino-6-nitro-3-ethoxycarbonyl-3-methyl-indolin-2-one 5-amino-6-nitro-3-ethyl indolin-2-one 5-amino-6-nitro-3-methoxycarbonyl-indolin-2-one 5-amino-6-nitro-3-methoxycarbonyl-3-methyl-indolin-2-one 5-amino-6-nitro-3-methyl indolin-2-one 5-amino-6-nitro-3- (3-pentyl) indolin-2-one 5-amino-6-nitro-3- (2-propyl) indolin-2-one 5-amino -6-nitro-3- (2-methylpropyl) indolin-2-one</li><li>5'-amino-6'-nitro-spiro [cyclohexane-1,3'-indoline] -2'-one 5'-amino-6'-nitro-spiro [cyclopentane-1,3'-indoline] -2 ' -on</li><li>5-amino-6-nitro-3,3-dimethyl-indoline-2-thione 5-amino-6-nitro-3-ethyl-indoline-2-thione 5-amino-6-nitro-3-methyl-indoline- 2-thion</li></ul>
<sub>E</sub>In addition to the compounds mentioned in the examples, compounds of the formula XXIV according to the invention are as follows<ul id="ul0009" list-style="none"><li>6-amino-5-nitro-indolin-2-one 6-amino-5-nitro-3-acetyl-indolin-2-one 6-amino-5-nitro-3-acetyl-3-methyl-indolin-2- on 6-amino-5-nitro-3-allyl-indolin-2-one 6-amino-5-nitro-3-cyano-3-methyl-indolin-2-one 6-amino-5-nitro-3-cyclohexyl -indolin-2-one 6-amino-5-nitro-3-cyclopentyl-indolin-2-one 6-amino-5-nitro-3,3-diallyl-indolin-2-one 6-amino-5-nitro- 3-ethoxycarbonyl-indolin-2-one 6-amino-5-nitro-3-ethoxycarbonyl-3-ethyl-indolin-2-one 6-a.mino-5-nitro-3-ethoxyearbonyl-3-methyl-indoline 2-one 6-amino-5-nitro-3-ethyl-indolin-2-one 6-amino-5-nitro-3-methoxycarbonyl-indolin-2-one 6-amino-5-nitro-3-methoxycarbonyl-3-methyl indolin-2-one 6-amino-5-nitro-3-methyl-indolin-2-one 6-amino-5-nitro-3- (3-pentyl) indolin-2-one 6-amino-5-nitro -3- (2-propyl) indolin-2-one 6'-amino-5'-nitro-spiro [cyclohexane-1,3'-indoline] -2 -'- one 6-amino-5-nitro-3 , 3-dimethyl-indoline-2-thione 6-amino-5-nitro-3-ethyl-indoline-2-thione 6-amino-5-nitro-3-methyl-indoline-2-thione</li></ul>
In addition to the compounds mentioned in the examples, compounds of the formula XIX according to the invention are the following:<ul id="ul0010" list-style="none"><li>5-nitro-6- (3-pyridinoylamino) indolin-2-one</li><li>3-acetyl-5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-acetyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one 3-acetyl-3-methyl 5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-acetyl-3-methyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one</li><li>3-allyl-5-<sub>B</sub>itro-6- (3-pyridinoylamino) indolin-2-one 3-allyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one</li><li>3-cyan-3-methyl-5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-cyan-3-methyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one</li><li>3-cyclohexyl-5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-cyclohexyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one 3-cyclopentyl-5-nitro- 6- (3-pyridinoylamino) indolin-2-one</li><li>3,3-diallyl-5-nitro-6- (3-pyridinoylamino) indolin-2-one 3,3-diallyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one</li><li>3,3-dimethyl-5-nitro-6- (2-pyridinoylamino) indolin-2-one 3,3-dimethyl-5-nitro-6- (2- (5-n-butylpyridinoylamino)) indoline -2-one 3,3-Dimethyl-5-nitro-6- (3- (6-cyanopyridinoylamino)) - indolin-2-one 3,3-dimethyl-5-nitro-6- (3- (6 -methyl-pyridinoylamino)) - indolin-2-one 3,3-dimethyl-5-nitro-6- (4- (2-methyl-pyridinoylamino)) - indolin-2-one 3,3-dimethyl-5-nitro -6- (4- (2-hydroxy-pyridinoylamino)) indolin-2-one</li><li>3-ethoxycarbonyl-5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-ethyl 5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-ethyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-methyl 5-nitro-6- (3-pyridinoylamino) indolin-2-one</li><li>3-methoxycarbonyl-5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-methoxycarbonyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one 3-methoxycarbonyl-3-methyl 5-nitro-6- (3-pyridinoylamino) indolin-2-one 3-methoxycarbonyl-3-methyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one</li><li>3- (3-pentyl) -5-nitro-6- (3-pyridinoylamino) indolin-2-one 3- (3-pentyl) -5-nitro-6- (4-pyridinoylamino) indolin-2-one 3- (2-propyl) -5-nitro-6- (3-pyridinoylamino) indolin-2-one</li><li>3- (2-methylpropyl) -5-nitro-6- (3-pyridinoylamino) indolin-2- one 3- (2-methylpropyl) -5-nitro-6- (4-pyridinoylamino) indoline -2-one</li><li>5'-nitro-6 '- (3-pyridinoylamino) -spiro [cyclohexane-1,3'-indoline] -2'-one S'-nitro-6' - (4-pyridinoylamino) -spiro [cyclohexane-1, 3'-indoline] -2'-one 5'-nitro-6 '- (3-pyridinyolamino) -spiro [cyclopentan-1,3'-indolinl-2'-one 5`-nitro-6' - (4- pyridinoylamina) -spiro [cyclopentan-1,3'-indoline] -1'-one</li><li>3,3-dimethyl-5-nitro-6- (2-pyridinoylamino) indoline-2-thione 3,3-dimethyl-5-nitro-6- (3-pyridinoylamino) indolin-2-thione 3,3- Dimethyl-5-nitro-6- (4-pyridinoylamino) indoline-2-thione</li><li>3-ethyl-5-nitro-6- (2-pyridinoylamino) indoline-2-thione 3-ethyl-5-nitro-6- (3-pyridinoylamino) indolin-2-thione 3-ethyl-5-nitro- 6- (4-pyridinoylamino) indoline-2-thione</li><li>3-methyl-5-nitro-6- (2-pyridinoylamino) indoline-2-thione 3-methyl-5-aitro-6- (3-pyridinoylamino) indoline-2-thione 3-methyl-5-nitro- 6- (4-pyridinoylamino) indoline-2-thione</li></ul>
In addition to the compounds mentioned in the examples, compounds of the general formula XX according to the invention are the following:<ul id="ul0011" list-style="none"><li>6-nitro-5- (3-pyridinoylamino) indolin-2-one 6-nitro-5- (4-pyridinoylamino) indolin-2-one</li><li>3-acetyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-acetyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-acetyl-3-methyl 6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-acetyl-3-methyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-allyl-6-nitro 5- (3-pyridinoylamino) indolin-2-one 3-allyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-cyano-3-methyl-6-nitro-5- (3rd pyridinoylamino) indolin-2-one 3-cyano-3-methyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-cyclohexyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-cyclohexyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-cyclopentyl-6-nitro- 5- (3-pyridinoylamino) indolin-2-one 3-cyclopentyl-6-nitro-5- (4-pyridizoylamino) indolin-2-one</li><li>3,3-diallyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one 3,3-diallyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3,3- Diethyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one 3,3-diethyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3,3-dimethyl-6- nitro-5- (2-pyridinoylamino) indolin-2-one 3,3-dimethyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one</li><li>3,3-dimethyl-6-nitro-5- (2- (5-n-butyl-pyridinoylamino) indolin-2-one</li><li>3,3-Dimethyl-6-nitro-5- (3- (6-cyanopyridinoylamino)) indolin-2-one</li><li>3,3-Dimethyl-6-nitro-5- (3- (6-methyl-pyridinoylamino)) indolin-2-one</li><li>3,3-Dimethyl-6-nitro-5- (4- (2-methyl-pyridinoylamino)) indolin-2-one</li><li>3,3-dimethyl-6-nitro-5- (4- (2-hydroxy-pyridinoylaminol)) indolin-2-one</li><li>3-ethoxycarbonyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-ethyl 6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-ethyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-methyl 6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-ethoxycarbonyl-3-methyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one</li><li>3-ethyl-6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-ethyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one</li><li>3-methoxycarbonyl-6-nitro-S- (3-pyridinoylamino) -indolin-2-one 3-methoxycarbonyl-6-nitro-S- (4-pyridinoylamino) -indolin-2-one 3-methoxycarbonyl-3-methyl- 6-nitro-5- (3-pyridinoylamino) indolin-2-one 3-methoxycarbonyl-3-methyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one 3-methyl-6-nitro 5- (3-pyridinoylamino) indolin-2-one 3-methyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one</li><li>3- (3-pentyl) -6-nitro-5- (3-pyridinoylamino) indolin-2-one 3- (3-pentyl) -6-nitro-5- (4-pyridinoylamino) indolin-2-one 3- (2-propyl) -6-nitro-5- (3-pyridinoylamino) indolin-2-one 3- (2-propyl) -6-nitro-S- (4-pyridinoylamino) indolin-2-one</li><li>3- (2-methyl-propyl) -6-nitro-5- (3-pyridinoylamino) -indolin-2-one .3- (2-methyl-propyl) -6-nitro-5- (4-pyridinoylamino) - indolin-2-one</li><li>6'-nitro-5 '- (3-pyridinoylamino) -spiro [cyclohexan-1,3'-indoline] -2'-one 6'-nitro-5' - (4-pyridinoylamino) -spirofcyclohexane-1,3 ' - indoline] -2'-one 61-nitro-5 '- (3-pyridinoylamino) -spiro [cyclopentan-1,3'-indoline) -2'-one 6'-nitro-S' - (4-pyridinoylamino) -spiro [cyclopentan-1,3'-indoline] -2'-one</li><li>3,3-dimethyl-6-nitro-5- (2-pyridinoylamino) indoline-2-thione 3,3-dimethyl-6-nitro-5- (3-pyridinoylamino) indolin-2-thione 3,3- Dimethyl-6-nitro-5- (4-pyridinoylamino) indoline-2-thione</li><li>3-ethyl-6-nitro-5- (2-pyridinoylamino) indoline-2<sup>t-</sup>thione 3-ethyl-6-nitro-5- (3-pyridinoylamino) indoline-2-thione 3-ethyl-6-nitro-5- (4-pyridinoylamino) indoline-2-thione 3-methyl-6-nitro -5- (2-pyridinoylamino) indoline-2-thione 3-methyl-6-nitro-5- (3-pyridinoylamino) indolin-2-thione 3-methyl-6-nitro-5- (4-pyridinoylamino) -indolin-2-thione</li></ul>
To convert the compounds of general formula I or their tautomeric forms into their pharmacologically acceptable salts, these are preferably set in an organic solvent with the equivalent amount of an inorganic or organic acid, for example hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, acetic acid, citric acid, Tartaric acid, maleic acid, fumaric acid, benzoic acid or cyclohexylsulfamic acid.
For the production of pharmaceuticals, the substances of the general formula I are mixed in a manner known per se with suitable pharmaceutical carrier substances, flavorings, flavors and colors and shaped, for example, as tablets or dragées or with the addition of appropriate auxiliaries in water or oil, such as olive oil, for example. suspended or dissolved.
The new substances of general formula I according to the invention and their salts can be administered enterally or parenterally in liquid or solid form. Water is preferably used as the injection medium, which contains the additives which are customary in injection solutions, such as stabilizing agents, solubilizers or buffers.
Such additives are, for example, tartrate and citrate buffers, ethanol, combined complexing agents (such as ethylenediaminetetraacetic acid and their non-toxic salts) and high molecular weight polymers (such as liquid polyethylene oxide) for viscosity regulation. Solid carrier materials are, for example Starch, lactose, mannitol, methyl cellulose, talc, highly disperse silica, high molecular weight fatty acids (such as steric acid), gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats and solid high molecular weight polymers (such as polyethylene glycols). For oral<sub>A</sub>Suitable preparations can optionally contain flavorings and sweeteners.
The compounds of the formula I according to the invention are usually applied in amounts of 10-500 mg per day based on 75 kg of body weight. It is preferred to administer 1-2 tablets with an active substance content of 5-200 mg 2-3 times a day. The tablets can also be delayed, which means that 1-2 tablets with 10-500 mg of active ingredient have to be given only once a day. The active substance can also be injected 1-8 times a day or given by continuous infusion, with amounts of 5-200 mg / day being usually sufficient.
In addition to the compounds mentioned in the examples, the following and their tautomers are preferred for the purposes of the present invention:<ul id="ul0012" list-style="none"><li>2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-acetyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-acetyl-2- (4-pyridyl) -6.7 -dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-acetyl-7-methyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2, 3-f] benzimidazol-6-one 7-acetyl-7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-allyl-2- (3-pyridiyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-allyl-2- (4-pyridyl) -6.7 dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-aminocarbonyl-7-methyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-aminocarbonyl-7-methyl-2- ( 4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-cyan-7-methyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-cyan-7-methyl-2- ( 4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-cyclohexyl-2- (3-pyridyl) -6,7-dihydro-3H, SH- pyrrolo [2,3-fJ-benzimidazol-6-one 7-cyclohexyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] -benzimidazol-6-one 7 -Cyclopentyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7,7-diallyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] -benzimidazol-6-one 7,7-diallyl-2- (4-pyridyl ) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] -benzimidazol-6-one 7,7-diethyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H- pyrrolo [2,3-f] benzimidazol-6-one 7,7-diethyl-2- (4-N-oxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f ] benzimidazol-6-one 7,7-diethyl-2- (4- (2-methyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7 , 7-Diethyl-2- (4-pyridyl-ethyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (2-N-oxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (2- (5-n-butyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (3- (6 -cyan-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (3- (6-hydroxy-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2, 3-f] benzimidazol-6-one 7,7-dimethyl-2- (3- (6-nitro-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6 -one 7,7-dimethyl-2- (4- (2-ethyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7,7-dimethyl -2-t4-t2-methoxy-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (4- (2- nitro-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (3-pyridyl-methyl) -6,7-dihydro -3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (3-pyridyl) -ethyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7,7-dimethyl-2- (4th -pyridyl-vinyl) -6,7-dihydro-3H, SH-pyrrolo- [2,3-f] benzimidazol-6-one</li><li>7-ethoxycarbonyl-2- (3-pyridyl) -6,7-dihydro-3H, SH-pyrrolo [2,3-f] -benzimidazol-6-one 7-ethoxycarbonyl-2- (4-pyridyl) -6, 7-dihydro-3H, SH-pyrrolo [2,3-f] benzimidazol-6-one 7-ethoxycarbonyl-7-ethyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [ 2,3-f] benzimidazol-6-one 7-ethoxycarbonyl-7-ethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-ethoxycarbonyl-7-methyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-ethyl-2- (3-N-oxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] -benzimidazol-6-one 7-ethyl-2- (4-N -oxypyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-hydrazinocarbonyl-7-methyl-2- (3-pyridyl) -6,7-diyhdro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-isopropylidene-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7-methoxycarbonyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one 7-methoxycarbonyl-2- (4-pyridyl) -6, 7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-methoxycarbonyl-7-methyl-2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [ 2,3-f] benzimidazol-6-one 7-methoxycarbonyl-7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7-methyl-2- (3-N-oxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one</li><li>7- (2-Methyl-propyl) -2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one 7- (2-methyl-propyl ) -2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one</li><li>7- (3-pentyl) -2- (3-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7- (3-pentyl) -2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7- (2-propyl) -2- (3-pyridyl) -6.7- dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 7- (2-propyl) -2- (4- (2-methyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one 2 '- (3-pyridyl) -spiro [cyclopropan-1.7'-6', 7'-diyhdro-3'H, 5'H-pyrrolo [2 ', 3'-f] benzimidazol-6'-one 2 '- (3-pyridyl) -spiro [cyclopentan-1,7'-6', 7'-dihydro-3'H, 5'H-pyrrolo [2 ', 3'-flbenzimidazol-6'-one 2' - (3-pyridyl) -spiro [cyclohexane-1,7'-6 ', 7'-dihydro-3'H, 5'H-pyrrolo [2', 3'-f] benzimidazol-6'-one 2 ' - (4-Pyridyl) -spiro [cyclohexane-1,7'-6 ', 7'-dihydro-3'H, 5'-pyrrolo [2', 3'-f] benzimidazol-6'-one</li><li>7,7-dimethyl-2- (2-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] -benzimidazole-6-thione 7,7-dimethyl-2- (3-pyridyl ) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione 7,7-dimethyl-2- (3- (6-methyl-pyridyl) -6,7-dihydro -3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione 7,7-dimethyl-2- (4- (2-methyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [ 2,3-ftbenzimidazole-6-thione</li><li>7-ethyl-2- (2-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione 7-ethyl-2- [3-pyridyl) -6.7 dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione 7-ethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione</li><li>7-Methyl-1 (2-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione 7-methyl-2- (3-pyridyl) -6,7-dihydro -3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione 7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole- 6-thion</li></ul>
example 1
7,7-dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one x 4 H20
To a solution of 5,6-diamino-3,3-dimethyl-indolin-2-one (2.9 g, 0.015 mol) in methylene chloride (30 ml) with triethylamine (4.4 ml, 0.032 mol), isonicotinic acid chloride hydrochloride (3 g, 0.017 mol) and continue stirring overnight. It is evaporated to dryness in vacuo, the residue is stirred several times with water, suction filtered and the crystals obtained in a solution of ethanol (100 ml) with conc. HC1 (10 ml) heated to reflux for approx. 12 h. The mixture obtained is evaporated to dryness in vacuo, stirred with water (20 ml) and with aqueous NH<sub>3</sub>-Solution neutralized. It is then filtered off, washed with water, dried and recrystallized from water with 30% ethanol. Yield 1.9 g (36% of theory), mp. 215 ° C.
Analogously to example 1, one obtains:<tables id="tabl0001" num="0001"><img file="EP0161632A2_D0028.tif" /></tables><tables id="tabl0002" num="0002"><img file="EP0161632A2_D0029.tif" /></tables><tables id="tabl0003" num="0003"><img file="EP0161632A2_D0030.tif" /></tables>The starting materials for the compounds claimed in Example 1 can be prepared as follows.
4,4-dimethyl-2H, 4H-isoquinoline-1,3-dione
<ul id="ul0013" list-style="none"><li>a) Cyan-o-tolunitrile (142 g, 1 mol) together with benzyltributylammonium bromide (10.8 g, 0.03 mol) in conc. NaOH solution (700 ml) added and methyl iodide (185 ml, 2 mol) added dropwise with ice cooling. The mixture is stirred for 2 h, suctioned off from the crystals, washed with water and dried. 170 g (100% of theory) of o-cyano-a, a-dimethyl-phenylacetic acid nitrile are obtained. Mp 84-88 ° C. The product obtained is in 90 percent. H<sub>2</sub>S0<sub>4</sub> (1500 ml) added, stirred for 3 hours, poured onto ice, the crystals were washed with water and dried. 167 g (88% of theory) of the title compound are obtained. Mp 119-120 ° C.</li><li>b) KOH (17.73 g, 0.32 mol) was dissolved in 26.5 ml of water and 106 ml of ethanol. In this solution, 1,3 (2H, 4H) -isoquinolinedione (25.55 g, 0.16 mol) was dissolved with heating. Methyl iodide (45.44 g, 0.32 mol) was added dropwise to the solution, which was cooled to room temperature. After 1 h at room temperature, stirring was continued at 80 ° C. for 1 h. Most of the ethanol was distilled off, 300 ml of hot water were added to the residue, the mixture was cooled and the crystals were filtered off with suction. The crystals were dissolved in a little 2N NaOH and with saturated NH<sub>4</sub>Cl solution precipitated and suctioned off. Treatment with activated carbon and recrystallization from ethanol gives the pure product 17 g (57%).</li></ul>
The following compounds can be obtained in an analogous manner via route a or b:<tables id="tabl0004" num="0004"><img file="EP0161632A2_D0031.tif" /></tables>
c)
4
, 4-dimethyl-7-nitro-2H, 4H-isoquinoline-1,3-dione
To a solution of 4,4-dimethyl-2H, 4H-isoquinoline-1,3-dione (195 g, 1 mol) in conc. H<sub>2</sub>SO<sub>4</sub> (1000 ml) becomes a solution of smoking HN0<sub>3</sub> (46.2 ml, 1.1 mol) in conc. H<sub>2</sub>SO<sub>4</sub> added dropwise at 20 ° C. The mixture is stirred at RT for one hour, poured onto ice, the crystals are filtered off with suction, washed well with water and dried. It is recrystallized from ethanol.<ul id="ul0014" list-style="none"><li>Yield: 206 g (85% of theory), mp 211-214 ° C</li></ul>
In an analogous manner, the following compounds can be obtained after route c:<tables id="tabl0005" num="0005"><img file="EP0161632A2_D0032.tif" /></tables>
d)
3,3-dimethyl-6-nitro-indolin-2-one
Bromine (54 ml, 1.05 mol) is added dropwise to a solution of NaOH (210 g, 5.25 mol) in water (1700 ml) at 0 ° C. and then 4,4-dimethyl-7-nitro-2H, 4H-isoquinoline- 1,3-dione (81.7 g, 0.35 mol) added. After stirring at RT for 1 h, the mixture is heated to 80 ° C. for about 1 h and, after cooling, is made acidic with acetic acid. It is suctioned off, washed well with water and dried.<ul id="ul0015" list-style="none"><li>Yield 49 g (68% of theory), mp 241-242 ° C.</li></ul>
The following compounds can be synthesized analogously to d:<tables id="tabl0006" num="0006"><img file="EP0161632A2_D0033.tif" /></tables>
e)
6-amino-3,3-dimethyl-indolin-2-one
A suspension of 6-nitro-3,3-dimethyl-indolin-2-one (146 g, 0.71 mol) in methanol (3.5 liters) with glacial acetic acid (300 ml) is added to 10 percent. Pd / C (16 g) hydrogenated at 40 ° C with good stirring. The subsequently clear solution is suctioned off from the catalyst and concentrated. Yield 125 g (100% of theory), mp 185-190 ° C.
The following compounds can be obtained analogously to e:<tables id="tabl0007" num="0007"><img file="EP0161632A2_D0034.tif" /></tables>
f)
6-acetamido-3,3-dimethyl-indolin-2-one
A suspension of 6-amino-3,3-dimethyl-indolin-2-one (32 g, 0.18 mol) in ethyl acetate (500 ml) is cooled <sub>E</sub>Acetic anhydride (20.4 g, 0.2 mol) was added dropwise and the mixture was stirred at RT for about 1 h. The resulting product is suctioned off, washed well with ethyl acetate and dried.<ul id="ul0016" list-style="none"><li>Yield: 37.8 g (96% of theory), mp 275-277 ° C.</li></ul>
According to f, the following connections are obtained in an analogous manner:<tables id="tabl0008" num="0008"><img file="EP0161632A2_D0035.tif" /></tables>
G)
6-acetamido-3,3-dimethyl-5-nitro-indolin-2-one
To a solution of 6-acetamido-3,3-dimethyl-indolin-2-one (35 g, 0.16 mol) in conc. H<sub>2</sub>SO<sub>4</sub> (200 ml) is cooled with a solution of smoking HN0<sub>3</sub> (7.6 ml, 0.18 mol) in conc. H<sub>2</sub>SO<sub>4</sub> (7.6 ml) was added dropwise. The mixture is stirred for an hour, poured onto ice, the crystals are suctioned off, washed well with water and dried.<ul id="ul0017" list-style="none"><li>Yield: 39 g (92% of theory), mp 276-280 ° C.</li></ul>
The following compounds can be obtained analogously according to g:<tables id="tabl0009" num="0009"><img file="EP0161632A2_D0036.tif" /></tables>
H)
6-amino-3,3-dimethyl-5-nitro-indolin-2-one
A solution of 6-acetamido-3,3-dimethyl-5-nitro-indolin-2-one (36.2 g, 0.14 mol) in ethanol (180 ml) with conc. NaOH (18 ml) is refluxed for approx. 2 h, then concentrated in vacuo<sup>p</sup>H 6 adjusted and cooled in an ice bath. The crystals obtained are filtered off, washed with water and dried. Yield 29.5 g (97% of theory), mp 247-248 ° C.
The following compounds can be obtained analogously to h:<tables id="tabl0010" num="0010"><img file="EP0161632A2_D0037.tif" /></tables>
i)
5,6-diamino-3,3-dimethyl-indolin-2-one
A solution of 6-amino-3,3-dimethyl-5-nitro-indolin-2-one (18.7 g, 0.085 mol) in methanol (200 ml) is added to 10%. Pd / C (1.9 g) hydrogenated at 40 ° C. It is suctioned off from the catalyst, concentrated and crystallized from ethanol. Yield: 15.6 g (96% of theory), mp 245-247 ° C.
According to regulation i, the following compounds can be obtained in an analogous manner:<tables id="tabl0011" num="0011"><img file="EP0161632A2_D0038.tif" /></tables>
Example 2
7,7-dimethyl-2- (4-pyridyl-methyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one x 1 H
2
0
A suspension of 5,6-diamino-3,3-dimethyl-indolin-2-one (7.3 g, 0.038 mol) in 4-pyridylacetic acid methyl ester (11.6 g, 0.077 mol) is added under N<sub>2</sub>-Atmosphere heated to 180 ° C with stirring for approx. 16 h. Then the excess ester is distilled off in vacuo and the residue obtained on silica gel (mobile phase: dichloromethane / NH<sub>3</sub>- total<ul id="ul0018" list-style="none"><li>Methanol 20: 1) separated. Yield:<sub>1</sub>.<sub>8</sub> G</li><li>( <sub>16 </sub>% of theory), mp 333-337 ° C (water / methanol 10: 1)</li></ul>
Example 3
7,7-dimethyl-2- (3- (2-methoxy-6-methyl-pyridyl)) - 6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one
A solution of 5,6-diamino-3,3-dimethyl-indolin-2-one (3.8 g, 0.02 mol) with 2-methoxy-6-methyl-pyridin-3-aldehyde (3 g, 0.02 mol) and toluenesulfonic acid (0.4 g, 0.002 mol) in ethanol (50 ml) is refluxed for approx. 1 h, air being passed through the reaction mixture after 30 min through a bin line. After cooling, the precipitated substance is filtered off with suction and the filtrate is concentrated in vacuo, stirred with water and extracted with dichloromethane. The organic phase is concentrated and the residue is crystallized from ether. The combined raw products are recrystallized again from ethyl acetate. Yield: 1.2 g (19% of theory), mp 296-298 ° C.
Analogously to example 3, one obtains:<tables id="tabl0012" num="0012"><img file="EP0161632A2_D0039.tif" /></tables>
Example 4
7,7-dimethyl-2- (4-N-oxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazo1-6-one x 3 H
2
0
A solution of 7,7-dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one (3.9 g, 0.014 mol) in glacial acetic acid ( 50 ml) with 30 percent. H<sub>2</sub>O<sub>2</sub> (20 ml) is stirred for 2 days at 50 ° C and then diluted with water. The precipitated substance is filtered off and recrystallized from dioxane / water 1: 1. Yield 1.4 g (34% of theory), mp 260-262 ° C.
Analogously to example 4, one obtains:<tables id="tabl0013" num="0013"><img file="EP0161632A2_D0040.tif" /></tables>
Example 5
2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one hydrochloride
0.2 g (0.67 mmol) of 6-isonicotinoylamino-5-nitro-indolin-2-one were suspended in 20 ml of glacial acetic acid, with 80 mg of 10 percent. Pd / coal added and hydrogenated at normal pressure. After the hydrogenation, the catalyst was separated off, concentrated and the residue was dissolved in alcohol, filtered and acidified with ethanolic hydrochloric acid. Sucking off and washing with ethanol gives 0.12 g (62.5%) of product. Mp> 300 ° C, MS (trimethylsilyl derivative): M<sup>+</sup> 394,466 M 73, 75, 379, 451
Analogously to example 5, one obtains:<tables id="tabl0014" num="0014"><img file="EP0161632A2_D0041.tif" /></tables><tables id="tabl0015" num="0015"><img file="EP0161632A2_D0042.tif" /></tables>The starting materials for the compounds claimed in Example 5 can be prepared as follows.
a)
6-isonicotinoylamino-5-nitro-indolin-2-one
5.5 g (21.7 mmol) of 6-isonicotinoylamino-indolin-2-one were dissolved in portions in 20 ml of concentrated sulfuric acid, cooled with ice and 2.19 g (21.7 mmol) of KN0<sub>3</sub> in concentrated H<sub>2</sub>SO<sub>4</sub> slowly added dropwise. After 2 hours, the solution was poured onto ice, neutralized and suctioned off. The residue was largely dissolved in 2N hydrochloric acid, filtered, treated with floridine, suction filtered and neutralized. 4.5 g (70%) of the title compound are obtained. Mp> 300 ° C
The following compounds are obtained in an analogous manner:<tables id="tabl0016" num="0016"><img file="EP0161632A2_D0043.tif" /></tables><tables id="tabl0017" num="0017"><img file="EP0161632A2_D0044.tif" /></tables>
b)
6-isonicotinoylamino-indolin-2-one
5.0 g (27.1 mmol) of 6-amino-indolin-2-one hydrochloride (Helv. Chim. Acta 20, 373, 1937) were suspended in 100 ml of methylene chloride and 3.7 ml (27.1 mmol) of triethylamine were added and the mixture was stirred for 10 min. 6.73 g (37.8 mmol) of isonicotinoyl chloride hydrochloride and 5.24 ml (37.8 mmol) of triethylamine were added with ice cooling. A further 3.7 ml (27.1 mmol) of triethylamine were then added dropwise. After 3 h the methylene chloride was distilled off, the residue was worked through with water and suction filtered. The residue was wiped with hot ethanol. 5.6 g (82%) of the title compound are obtained. Mp 315-320 ° C
The following connection is obtained in an analogous manner:<tables id="tabl0018" num="0018"><img file="EP0161632A2_D0045.tif" /></tables><tables id="tabl0019" num="0019"><img file="EP0161632A2_D0046.tif" /></tables>
Example 6
7,7-diethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one x CH30H
Isonicotinic acid chloride hydrochloride (5.4 g, 0.03) is added in portions to a solution of 5,6-diamino-3,3-diethyl-indolin-2-one (4.4 g, 0.02 mol) in methylene chloride (100 ml) with triethylamine (8.4 ml) mol), after about 2 h glacial acetic acid is added and the crystals obtained are filtered off, washed and dried. Then in a mixture of ethanol (100 ml) with conc. HCl (20 ml) heated to reflux for about 20 h, evaporated in vacuo, the residue with NH<sub>3</sub>- Solution digested, suction filtered and dried. Then on silica gel (eluent: methylene chloride / NH<sub>3</sub>-saturated methanol 15: 1) purified and crystallized from methanol. Yield: 2.4 g (35% of theory), mp. 216-219 ° C
Analogously to example 6, one obtains:<tables id="tabl0020" num="0020"><img file="EP0161632A2_D0047.tif" /></tables>
The starting materials for the compounds claimed in Example 6 can be prepared as follows:
a)
5,6-diamino-3,3-diethyl-indolin-2-one
A solution of 5-amino-3,3-diethyl-6-nitro-indolin-2-one (10 g, 0.041 mol) in ethanol (150 ml) is added to 10 percent. <sub>P</sub>d / C (0.6 g) hydrogenated at RT. It is suctioned off from the catalyst, concentrated and recrystallized from ethanol.<ul id="ul0019" list-style="none"><li>Yield: 8.5 g (97% of theory), mp. 167-173 ° C.</li></ul>
According to regulation a, the following compounds can be obtained in an analogous manner:<tables id="tabl0021" num="0021"><img file="EP0161632A2_D0048.tif" /></tables>
b)
.5-Amino-3,3-diethyl-6-nitro-indolin-2-one
A solution of 5-acetamido-3,3-diethyl-6-nitro-indolin-2-one (72 g, 0.25 mol) in ethanol (500 ml) with conc. HC1 (100 ml) is refluxed for about 3 h, diluted with water (1000 ml), suction filtered and the crystals obtained are washed with aqueous ethanol and dried.<ul id="ul0020" list-style="none"><li>Yield: 54.7 g (89% of theory), mp. 267-272 ° C.</li></ul>
The following compounds can be obtained analogously to b:<tables id="tabl0022" num="0022"><img file="EP0161632A2_D0049.tif" /></tables>
c)
5-
A
cetamido-3,3-diethyl-6-nitro-indolin-2-one
HN0 is fumed with cooling to a solution of 5-acetamido-3,3-diethyl-indolin-2-one (84 g, 0.34 mol) in acetic anhydride (800 ml)<sub>3</sub> (24 ml) were added dropwise and the mixture was stirred at RT for about 2 h. It is carefully poured into ice water and the crystals obtained are suction filtered, washed with water and dried.<ul id="ul0021" list-style="none"><li>Yield: 72 g (72% of theory), mp. 182-184 ° C.</li></ul>
The following compounds can be obtained analogously according to regulation c:<tables id="tabl0023" num="0023"><img file="EP0161632A2_D0050.tif" /></tables>
d)
5-acetamido-3,3-diethyl-indolin-2-one
A suspension of 3,3-diethyl-5-nitro-indolin-2-one (86 g, 0.372 mol) in ethanol (700 ml) is added to 10 percent. Pd / C (4 g) hydrogenated with good stirring. Then the clear solution is suctioned off and a sample is crystallized from ethanol (mp. 188-190 ° C.), the main amount of the solution is carefully mixed with acetic anhydride (50 ml) and evaporated in vacuo. The residue is digested with ethyl acetate, suction filtered, washed and dried. Crystallization from ethyl acetate.<ul id="ul0022" list-style="none"><li>Yield: 85 g (94% of theory), mp. 196-197 ° C.</li></ul>
After d the following connections are obtained in an analogous manner:<tables id="tabl0024" num="0024"><img file="EP0161632A2_D0051.tif" /></tables>
e)
3,3-diethyl-5-nitro-indolin-2-one
To a solution of 3,3-diethyl-indolin-2-one (86 g, 0.462 mol) in 80 percent. H<sub>2</sub>SO<sub>4</sub> (500 ml) becomes a solution of smoking ENT with cooling<sub>3</sub> (17 ml) in 80 percent. H<sub>2</sub>SO (200 ml) was added dropwise. The mixture is stirred for about 30 minutes, poured onto ice, suction filtered, washed with water and dried.<ul id="ul0023" list-style="none"><li>Yield: 86 g (79% of theory), mp. 174-176 ° C.</li></ul>
The following compounds can be obtained analogously according to e:<tables id="tabl0025" num="0025"><img file="EP0161632A2_D0052.tif" /></tables>
Example 7
7-isopropylidene-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one
In a suspension of 2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one (0.4 g, 1.6 mmol) in ethanol (20 ml) with acetone (10 ml) ammonia is introduced until saturated and stirred at 60 ° C. for 2 h. Then acetone (10 ml) is added again and the mixture is stirred at 60 ° C. for 4 h, then the mixture is concentrated, taken up in ethanol, acidified and suctioned off from the precipitate. The residue obtained is dissolved in water, neutralized, suction filtered from the crystals and recrystallized from isopropanol / ethyl acetate. Yield: 40 mg (9% of theory), mp> 300 ° C.
Example 8
7-ethoxycarbonyl-7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrola [2,3-f] benzimidazol-6-one x HCl
A solution of 5-amino-3-ethoxycarbonyl-3-methyl-6- (4-pyridinoylamino) indolin-2-one (10.85 g, 32.2 mmol) in ethanol (700 ml) with conc. HCl (50 ml) is heated to reflux for about 12 h. The mixture is then cooled, concentrated somewhat, suctioned off from the crystals and recrystallized from ethanol.<ul id="ul0024" list-style="none"><li>Yield: 9.6 g (79% of theory), mp. 288-290 ° C.</li></ul>
The starting materials for the compounds claimed in Example 8 can be prepared as follows:
a)
5-amino-3-ethoxycarbonyl-3-methyl-6- (4-pyridinoylamino) indolin-2-one
A solution of 3-ethoxycarbonyl-3-methyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one (12.4 g, 32.2 mmol) in ethanol (500 ml) is added to 10 percent. Pd / C (1 g) hydrogenated at room temperature. It is suctioned off from the catalyst, concentrated and the substance obtained is immediately used further.
b)
3-ethoxycarbonyl-3-methyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one
To a solution of 3-ethoxycarbonyl-3-methyl-6- (4-pyridinoyl-amino) -indolin-2-one (13 g, 0.038 mol) in conc. H<sub>2</sub>SO<sub>«</sub> (90 ml) a solution of potassium nitrate (3.9 g, 0.038 mol) in conc. HzSO<sub>4</sub> (30 ml) was added dropwise. It is stirred for about an hour, poured onto ice, under cooling with conc. NH<sub>3</sub>Solution adjusted to pH 8, the crystals suctioned off and recrystallized from ethanol / methylene chloride. Yield: 12.81 g (82% of theory), mp. 217-219 ° C.
c)
3-ethoxycarbonyl-3-methyl-6- (4-pyridinoylamino) indolin-2-one
To a cooled solution of 6-amino-3-ethoxycarbonyl-3-methyl-indolin-2-one (13 g, 0.048 mol) in methylene chloride (500 ml), triethylamine (22.1 ml) and pyridine-4-carbonoyl chloride hydrochloride (9.4 g, 0.053 mol) and stirred for about 2 h at RT. The mixture is then evaporated to dryness with water, filtered off with suction and the residue is recrystallized from ethanol / methylene chloride. Yield:<ul id="ul0025" list-style="none"><li>11.9 g (73% of theory), mp. 222-224 ° C.</li></ul>
d)
6-amino-3-ethoxycarbonyl-3-methyl-indolin-2-one
A solution of methyl (2,4-dinitro-phenyl) malonic acid diethyl ester (27 g, 0.079 mol) in ethanol (800 ml) is added to 10 percent. Pd / C (1 g) hydrogenated at RT. It is then suctioned off from the catalyst, acidified with ethanolic HCl, concentrated and crystallized out by adding isopropanol. Yield: 13.19 g (71% of theory), mp. 248 ° C.
Example 9
7-hydrazinocarbonyl-7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one
A solution of 7-ethoxycarbonyl-7-methyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one hydrochloride (1 g, 2.7 mmol) in ethanol (30 ml) with hydrazine hydrate (6 ml) is stirred at 80 ° C. for about 8 h. It is then suctioned off, boiled with a solution of methanol (1000 ml) with methylene chloride (500 ml), concentrated somewhat and the crystals are suctioned off, washed with methanol and dried.<ul id="ul0026" list-style="none"><li>Yield: 0.6 g (70% of theory), mp> 300 ° C.</li></ul>
Example 10
7,7-dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one x 4 H
2
0
A solution of 3,3-dimethyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one (68 g, 0.209 mol) in ethanol (3000 ml) with triethylamine (30 ml) is added to 10 percent. Pd / C hydrogenated. The catalyst is then suctioned off, concentrated and the crude product in ethanol (1000 ml) with conc. HCl (200 ml) heated at reflux for about 6 h, concentrated, diluted with water and adjusted to pH 8 with ammonia water. The resulting crystals are filtered off, washed and crystallized from ethanol / water. Yield: 52.3 g (71% of theory), mp. 215 ° C.
Analogously to Example 10, the following is obtained:<tables id="tabl0026" num="0026"><img file="EP0161632A2_D0053.tif" /></tables>
The starting materials from Example 10 are produced as follows:
a)
3,3-dimethyl-5-nitro-6- (4-pyridinoylamino) indolin-2-one
A solution of 6-amino-3,3-dimethyl-5-nitro-indolin-2-one (48.3 g, 0.22 mol) in pyridine (400 ml) is added in portions with isonicotinic acid chloride hydrochloride (78.8 g, 0.44 mol) and approx 2 hours of stirring. It is then poured into water, neutralized, suction filtered and recrystallized from ethanol.<ul id="ul0027" list-style="none"><li>Yield: 68.1 g (95% of theory), mp. 225-230 ° C.</li></ul>
The following compounds are obtained analogously to regulation a):<tables id="tabl0027" num="0027"><img file="EP0161632A2_D0054.tif" /></tables>
Example 11
7- (2-methyl-propyl) -2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo- [2,3-f] benzimidazol-6-one x 1.5 H
2
0
To a solution of 5,6-diamino-3- (2-methyl-propyl) -indolin-2-one (1.3 g, 0.006 mol) in methylene chloride (40 ml) with triethylamine (3 ml) is added in portions isonicotinic acid chloride hydrochloride ( 1.6 g, 0.009 mol), extracted after about 2 h with water and concentrated the organic phase. The solid residue is dissolved in ethanol (70 ml) with conc. HC1 (10 ml) heated at reflux overnight, concentrated, stirred with aqueous ammonia and extracted with methylene chloride / methanol. The organic phase is concentrated and on silica gel (mobile phase: methylene chloride / NH<sub>3</sub>-saturated methanol 9: 1) cleaned. Yield: 0.65 g (35% of theory), mp. 200-202 ° C.
Starting materials for Example 11 are obtained in the following way:
a)
5,6-diamino-3- (2-methyl-propyl) indolin-2-one
A solution of 6-amino-3- (2-methyl-propyl) -5-nitro-indolin-2-one (1.5 g, 0.006 mol) in methanol (50 ml) is added to 10 percent. Pd / C (0.3 g) hydrogenated. It is suctioned off from the catalyst, concentrated and recrystallized from ethanol.<ul id="ul0028" list-style="none"><li>Yield: 1.3 g (99% of theory)</li></ul>
b)
6-amino-3- (2-methyl-propyl) -5-nitro-indolin-2-one
A solution of 6-acetamido-3- (2-methyl-propyl) -5-nitro-indolin-2-one (2.9 g, 0.01 mol) in ethanol (50 ml) with conc. HCl (3 ml) is refluxed for approx. 30 min, concentrated and concentrated on silica gel (mobile solvent: methylene chloride / methanol NH<sub>3</sub> saturated 20: 1) cleaned.<ul id="ul0029" list-style="none"><li>Yield: 1.5 g (60% of theory)</li></ul>
c)
6-acetamido-3- (2-methyl-propyl) -5-nitro-indolin-2-one
A solution of 6-acetamido-3- (2-methyl-propyl) indolin-2-one (4.2 g, 0.017 mol) in acetic anhydride (50 ml) is cooled with smoking HN0<sub>3</sub> (0.8 ml, 0.019 mol) were added and the mixture was stirred for about 30 min. Then it is carefully poured onto ice and the crystals are suctioned off, washed with water and dried.<ul id="ul0030" list-style="none"><li>Yield: 3.2 g (66% of theory), mp. 192-197 ° C.</li></ul>
d)
6-acetamido-3- (2-methyl-propyl) indolin-2-one
A solution of 6-acetamido-3-isopropylidene-indolin-2-one (6.4 g, 0.026 mol) in methanol (100 ml) is added to 10 percent. Pd / C (0.6 g) hydrogenated. The catalyst is then suctioned off and the solution is evaporated to dryness.<ul id="ul0031" list-style="none"><li>Yield: 5.5 g (84% of theory), mp. 214-216 ° C.</li></ul>
e)
6-acetamido-3-isopropylidene-indolin-2-one
A solution of NaOH (1.9 g) in water (2 ml) is added to a suspension of 6-acetamido-indolin-2-one (9 g, 0.047 mol) in ethanol (50 ml) with isobutyraldehyde (3.4 g, 0.047 mol). dripped. After about 5 h, the mixture is evaporated to dryness in vacuo and on silica gel (mobile phase: methylene chloride / methanol NH<sub>3</sub> saturated) cleaned.<ul id="ul0032" list-style="none"><li>Yield: 7.6 g (65% of theory) of foam, mp 93 ° C.</li></ul>
Example 12
7,7-dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazole-6-thione x 2 H
2
0
A solution of 7,7-dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-flbenzimidazol-6-one (2.0 g, 7.2 mmol) in pyridine (35 ml ) with P<sub>4</sub>S<sub>10</sub> (4 g) heated to 100 ° C for 5 h with good stirring. It is then decomposed with ice water, made alkaline, the desired substance extracted and on silica gel (mobile phase: methylene chloride / NH<sub>3</sub> saturated methanol 20: 1) cleaned.<ul id="ul0033" list-style="none"><li>Yield: 1.7 g (72% of theory), mp. 205-220 ° C.</li></ul>
Example 13
7,7-dimethyl-2- (4- (3-hydroxy-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-flbenzimidazol-6-one
To a mixture of 3-hydroxy-pyridine-4-carboxylic acid (2.8 g, 0.02 mol) in DMF (30 ml) with anhydrous CaSO<sub>4</sub> (3 g) and hydroxybenzotriazole (3.4 g, 0.025 mol), a solution of DCC (5.2 g, 0.025 mol) in DMF (20 ml) is added with stirring at 0 ° C. Then 5,6-diamino-3,3-dimethyl-indolin-2-one (2.8 g, 0.015 mol) is added and, after stirring briefly, concentrated, digested with water and suction filtered. The residue is washed with ethanol (200 ml) and conc. HCl (40 ml) heated at reflux for 2 d, suction filtered after cooling and the filtrate concentrated in vacuo, digested with ammonia water and suction filtered. It is purified by column chromatography on silica gel (mobile phase: methylene chloride / methanol / acetic acid 10: 1: 1).<ul id="ul0034" list-style="none"><li>Yield: 1.4 g (24% of theory), mp> 300 ° C.</li></ul>
Analogously to example 13, one obtains:<tables id="tabl0028" num="0028"><img file="EP0161632A2_D0055.tif" /></tables>
Example 14
7,7-dimethyl-2- (4- (pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one
A solution of 3,3-dimethyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one (33 g, 0.1 mol) in ethanol (1300 ml) with triethylamine (13 ml) is added to 10 percent. Pd / C hydrogenated. It is then suctioned off from the catalyst, concentrated and concentrated in ethanol (500 ml) with. HCl (100 ml) heated to reflux for about 6 h. It is concentrated, digested with ammonia water and the product formed is suction filtered, washed with water, crystallized from ethanol / water and recrystallized from methanol.<ul id="ul0035" list-style="none"><li>Yield: 19.5 g (70% of theory), mp. 285-288 °<sub>C.</sub>.</li></ul>
The starting compounds are made as follows:
a)
3,3-dimethyl-6-nitro-5- (4-pyridinoylamino) indolin-2-one
To a solution of 3,3-dimethyl-5- (5-pyridinoylamino) indolin-2-one (5.5 g, 0.02 mol) in glacial acetic acid (50 ml), smoking HN0 with cooling<sub>3</sub> (2.5 ml) were added dropwise and the mixture was stirred at RT for about 2 h. It is carefully poured onto ice, neutralized and the crystals obtained are suction filtered, washed with water and dried.<ul id="ul0036" list-style="none"><li>Yield: 5.2 g (81% of theory), mp. 310-318 ° C (from methanol)</li></ul>
b)
3,3-dimethyl-5- (4-pyridinoylamino) indolin-2-one
A suspension of 5-amino-3,3-dimethyl-indolin-2-one (5.0 g, 0.028 mol) in methylene chloride (100 ml) with triethylamine (14 ml) is cooled with isonicotinic acid chloride hydrochloride (7.0 g, 0.04 mol) transferred. It is then concentrated, digested with water, suction filtered and recrystallized from ethanol.<ul id="ul0037" list-style="none"><li>Yield: 5.8 g (73% of theory), mp> 300 ° C.</li></ul>
c)
5-amino-3,3-dimethyl-indolin-2-one
A suspension of 5-nitro-indolin-2-one (100 g, 0.48 mol) in methanol (2500 ml) with glacial acetic acid (200 ml) is added to 10%. Pd / C (10 g) hydrogenated at 40 ° C with good stirring. The subsequent clear solution is suctioned off from the catalyst and concentrated.<ul id="ul0038" list-style="none"><li>Yield: 82 g (96% of theory<sub>T</sub>H.), <sub>M</sub>p. 185-191 ° C (HCl salt from methanol).</li></ul>
d)
3,3-dimethyl-5-nitro-indolin-2-one
To a solution of 3,3-dimethyl-indolin-2-one (100 g, 0.62 mol) in 80 percent. H<sub>2</sub>SO<sub>4</sub> (500 ml) becomes a solution of smoking HN0 with cooling<sub>3</sub> (22 ml) in 80% H<sub>2</sub>SO<sub>4</sub> (200 ml) was added dropwise. It is stirred for about 30 minutes<sub>E</sub>is poured, suction filtered, washed with water and dried.<ul id="ul0039" list-style="none"><li>Yield: 100 g (78% of theory), mp. 192-196 ° C (ethyl acetate / heptane).</li></ul>
Example 15
7,7-dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] benzimidazol-6-one x 4 H
2
0
To a solution of 5-amino-3,3-dimethyl-6-nitro-indolin-2-one (5 g, 0.023 mol) in pyridine (50 ml), isonicotinic acid chloride hydrochloride (8 g, 0.04 mol) is added in portions and approx 2 hours of stirring. Then it is poured onto water, digested with ammonia water, suction filtered, washed with water and the residue in ethanol (300 ml) with triethylamine (3 ml) at 10%. Pd / C hydrogenated. It is suctioned off from the catalyst, concentrated and the crude product in ethanol (100 ml) with conc. HCl (20 ml) heated at reflux for about 6 h, concentrated, neutralized and the product obtained was suction filtered, washed and crystallized from ethanol / water. Yield: 5.5 g (69% of theory), mp. 215 ° C.
Analogously to example 15, one obtains:<tables id="tabl0029" num="0029"><img file="EP0161632A2_D0056.tif" /></tables><tables id="tabl0030" num="0030"><img file="EP0161632A2_D0057.tif" /></tables>
Example 16
7,
7
-Dimethyl-2- (4-pyridyl) -6,7-dihydro-3H, 5H-pyrrolo [2,3-f] -benzimidazol-6-one x 4 H
2
O
To a solution of 6-amino-5-nitro-3,3-dimethyl-indolin-2-one (221 mg, 1 mmol) in DMF (2 ml) with pyridine (0.5 ml) and isonicotinic acid (123 mg, 4 mmol ) you give POC1<sub>3</sub> (0.15 ml), left to stir for about 3 h, poured onto ice water and suctioned off the crystals obtained. The mixture is then hydrogenated in Pd / C with triethylamine (0.2 ml) in ethanol (10 ml), suction filtered from the catalyst, concentrated and concentrated in a solution of ethanol (5 ml) with conc. HC1 (1 ml) heated to reflux. It is concentrated, digested with ammonia water and recrystallized from ethanol / water.<ul id="ul0040" list-style="none"><li>Yield: 220 mg (63% of theory), <sub>M</sub>p. 215 ° C.</li></ul>
Analogously to example 16, one obtains:<tables id="tabl0031" num="0031"><img file="EP0161632A2_D0058.tif" /></tables><tables id="tabl0032" num="0032"><img file="EP0161632A2_D0059.tif" /></tables>
Contents4
73 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP0257334A2 | Cited by | European Patent Office (EPO) | Search report |
| WO2015021358A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| WO2014151206A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| WO2012118972A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| WO2014040969A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| EP0207483A2 | Cited by | European Patent Office (EPO) | Examiner |
| EP3884935A1 | Cited by | European Patent Office (EPO) | Applicant |
| US5212186A | Cited by | United States of America | Search report |
| EP0257334A3 | Cited by | European Patent Office (EPO) | Search report |
| EP0214592B1 | Cited by | European Patent Office (EPO) | Examiner |
| EP0271040A3 | Cited by | European Patent Office (EPO) | Search report |
| WO2014197720A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| EP0189103A3 | Cited by | European Patent Office (EPO) | Search report |
| US8063225B2 | Cited by | United States of America | Applicant |
| WO2020237096A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| EP3718557A2 | Cited by | European Patent Office (EPO) | Applicant |
| EP0214592A2 | Cited by | European Patent Office (EPO) | Examiner |
| US4695567A | Cited by | United States of America | Search report |
| EP0318902A2 | Cited by | European Patent Office (EPO) | Search report |
| EP3708179A1 | Cited by | European Patent Office (EPO) | Applicant |
| EP0318902A3 | Cited by | European Patent Office (EPO) | Search report |
| WO2013138352A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| WO2011069038A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| EP0473963A1 | Cited by | European Patent Office (EPO) | Search report |
| EP0322746A1 | Cited by | European Patent Office (EPO) | Search report |
| EP2998314A1 | Cited by | European Patent Office (EPO) | Applicant |
| EP0186010A1 | Cited by | European Patent Office (EPO) | Search report |
| WO2014131024A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| EP3241839A1 | Cited by | European Patent Office (EPO) | Applicant |
| WO2014151200A2 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| EP0189103A2 | Cited by | European Patent Office (EPO) | Search report |
| US8686005B2 | Cited by | United States of America | Applicant |
| US4963677A | Cited by | United States of America | Search report |
| EP2923706A1 | Cited by | European Patent Office (EPO) | Applicant |
| EP2088154A1 | Cited by | European Patent Office (EPO) | Applicant |
| EP0207483B1 | Cited by | European Patent Office (EPO) | Examiner |
| EP0268178A1 | Cited by | European Patent Office (EPO) | Search report |
| US4963686A | Cited by | United States of America | Search report |
| EP2810951A2 | Cited by | European Patent Office (EPO) | Applicant |
| EP0271040A2 | Cited by | European Patent Office (EPO) | Search report |
| US4710510A | Cited by | United States of America | Search report |
| EP3492106A1 | Cited by | European Patent Office (EPO) | Applicant |
| EP0098448A2 | Cites | European Patent Office (EPO) | Search report |
| GB1158532A | Cites | United Kingdom | Search report |
53 members in 22 offices
Priority claims10
| Document | Office | Kind | Date |
|---|---|---|---|
| 3417643 | Germany | A | |
| 3417643 | Germany | A | |
| 3417643 | Germany | – | |
| 3446417 | Germany | A | |
| 3446417 | Germany | A | |
| 3446417 | Germany | – | |
| 3417643 | – | – | – |
| 3446417 | – | – | – |
| DE19843417643 | – | – | – |
| DE19843446417 | – | – | – |
Members53
| Document | Office | Kind | |
|---|---|---|---|
| DK209585D0 | Denmark | D0 | |
| FI851869A0 | Finland | A0 | |
| PT80425A | Portugal | A | |
| IL75120A0 | Israel | A0 | |
| IL75120D0 | Israel | D0 | |
| DK209585A | Denmark | A | |
| FI851869L | Finland | L | |
| NO851862L | Norway | L | |
| AU4222285A | Australia | A | |
| DE3417643A1 | Germany | A1 | |
| EP0161632A2This record | European Patent Office (EPO) | A2 | |
| GR851085B | Greece | B | |
| JPS60246386A | Japan | A | |
| KR850008170A | Republic of Korea | A | |
| ES542976A0 | Spain | A0 | |
| ES8603178A1 | Spain | A1 | |
| ZA853375B | South Africa | B | |
| HUT37938A | Hungary | A | |
| DD234867A5 | German Democratic Republic (until 1990) | A5 | |
| EP0161632A3 | European Patent Office (EPO) | A3 | |
| DE3446417A1 | Germany | A1 | |
| CN85103724A | China | A | |
| PL253246A1 | Poland | A1 | |
| AU560349B2 | Australia | B2 | |
| PT80425B | Portugal | B | |
| US4666923A | United States of America | A | |
| KR870001201B1 | Republic of Korea | B1 | |
| KR870001202B1 | Republic of Korea | B1 | |
| HU193754B | Hungary | B | |
| IL84769A0 | Israel | A0 | |
| IL84769D0 | Israel | D0 | |
| CN85103724B | China | B | |
| FI883391A | Finland | A | |
| FI883391A0 | Finland | A0 | |
| PL144822B1 | Poland | B1 | |
| PH22863A | Philippines | A | |
| IL75120A | Israel | A | |
| IL84769A | Israel | A | |
| SU1480770A3 | Soviet Union (until 1991) | A3 | |
| PL147239B1 | Poland | B1 | |
| NZ212005A | New Zealand | A | |
| PL147842B1 | Poland | B1 | |
| PL148017B1 | Poland | B1 | |
| FI81351B | Finland | B | |
| FI81351C | Finland | C | |
| US4963686A | United States of America | A | |
| EP0161632B1 | European Patent Office (EPO) | B1 | |
| AT62487T | Austria | T | |
| ATE62487T1 | Austria | T1 | |
| DE3582447D1 | Germany | D1 | |
| JPH0647593B2 | Japan | B2 | |
| JPH0741474A | Japan | A | |
| JPH0772185B2 | Japan | B2 |
38 legal events, as 3 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Notification of lapseLapsedST | ST | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Fr: translation filedET | ET | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Designated contracting statesAK | AK | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0161632
- Publication, DOCDB
- 0161632
- Publication, EPODOC
- EP0161632
- Application
- 85105675
- Application, DOCDB
- 85105675
- Application, EPODOC
- EP19850105675
Titles6
- German
- Neue Pyrrolo-Benzimidazole, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel sowie Zwischenprodukte
- English
- Pyrrolo-benzimidazoles, process for their preparation, medicaments containing them and intermediates
- French
- Pyrrolo benzimidazoles, procédé pour leur préparation, médicaments les contenant et intermédiaires
- German
- Neue Pyrrolo-Benzimidazole, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel sowie Zwischenprodukte.
- English
- Pyrrolo-benzimidazoles, process for their preparation, medicaments containing them and intermediates.
- French
- Pyrrolo benzimidazoles, procédé pour leur préparation, médicaments les contenant et intermédiaires.
Classification
- CPC, 11
- C07D487/04
- C07D487/14
- A61P9/00
- C07D209/34
- A61P9/04
- C07D209/42
- A61P9/12
- C07D209/96
- C07D401/12
- C07D487/10
- C07D403/14
- IPC, 14
- A61K31 4184
- A61K31 44
- A61P9 00
- A61P9 04
- A61P9 12
- C07D209 34
- C07D209 42
- C07D209 96
- C07D401 12
- A61K31 415
- C07D403 14
- C07D487 04
- C07D487 10
- C07D487 14
Designated states11
- Contracting states, 11
- Austria
- Belgium
- Switzerland
- Germany
- France
- United Kingdom
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden